Create Medicines secured Human Research Ethics Committee approval in Australia to initiate a first-in-human study of CRT-402, its lead in vivo CAR T candidate for autoimmune diseases. The company’s move advances the preclinical program into early clinical testing. The trial authorization is an early regulatory milestone that can help define dosing, safety, and preliminary pharmacodynamic activity for an in vivo approach, where CAR constructs are delivered within the body rather than via ex vivo cell manufacturing. Industry attention will likely center on immune safety and control of on-target activity, particularly for autoimmune indications where benefit-risk is tightly dependent on the ability to modulate immune pathways without excessive inflammation.